Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.62
+0.29 (5.44%)
At close: Mar 9, 2026, 4:00 PM EDT
5.61
-0.01 (-0.18%)
After-hours: Mar 9, 2026, 7:56 PM EDT
Immuneering Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Mar '26 Mar 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 363 | 425 | 68 | 215 | 128 | 426 | |
| Market Cap Growth | 583.44% | 521.96% | -68.25% | 67.99% | -69.91% | - | |
| Enterprise Value | 194 | 201 | 22 | 122 | 16 | 267 | |
| Last Close Price | 5.62 | 6.58 | 2.20 | 7.35 | 4.85 | 16.17 | |
| PS Ratio | - | - | - | - | 404.05 | 204.62 | |
| PB Ratio | 1.66 | 1.95 | 1.65 | 2.38 | 1.17 | 2.73 | |
| P/TBV Ratio | 1.72 | 2.01 | 1.99 | 2.58 | 1.25 | 2.86 | |
| EV/Sales Ratio | - | - | - | - | 49.59 | 128.17 | |
| Debt / Equity Ratio | 0.02 | 0.02 | 0.10 | 0.05 | 0.04 | 0.03 | |
| Net Debt / Equity Ratio | -0.77 | -0.77 | -0.77 | -0.90 | -0.92 | -0.93 | |
| Net Debt / EBITDA Ratio | 2.86 | 2.86 | 0.50 | 1.40 | 1.96 | 4.28 | |
| Net Debt / FCF Ratio | 3.72 | 3.72 | 0.58 | 1.65 | 2.25 | 4.68 | |
| Asset Turnover | - | - | - | - | 0.00 | 0.02 | |
| Quick Ratio | 17.16 | 17.16 | 4.82 | 10.92 | 13.10 | 26.53 | |
| Current Ratio | 17.50 | 17.50 | 5.28 | 11.36 | 13.50 | 27.04 | |
| Return on Equity (ROE) | -43.12% | -43.12% | -92.51% | -53.36% | -38.00% | -35.00% | |
| Return on Assets (ROA) | -26.07% | -26.07% | -51.57% | -32.46% | -22.38% | -20.65% | |
| Return on Capital Employed (ROCE) | -26.80% | -26.80% | -141.70% | -61.70% | -45.30% | -21.00% | |
| Earnings Yield | -15.44% | -13.19% | -89.35% | -24.86% | -39.44% | -7.88% | |
| FCF Yield | -12.53% | -10.71% | -80.64% | -22.92% | -35.02% | -7.26% | |
| Buyback Yield / Dilution | -46.80% | -46.80% | -5.51% | -7.69% | -93.84% | -175.00% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.